Total CMS (mean, SD) | IFC group (n = 18) | Sham group (n = 17) | p** |
---|---|---|---|
Post-treatment | 57 ± 7.7 | 48.2 ± 12 | 0.727 |
6th week post-treatment | 69 ± 8.9 | 60.7 ± 12.1 | |
18th week post-treatment | 79.6 ± 9.4 | 69.3 ± 14.2 | |
p* | < 0.001 | < 0.001 | |
CMS subscores | |||
Pain | |||
Post-treatment | 9.1 ± 3.2 | 7.9 ± 4.8 | |
6th week post-treatment | 11.8 ± 2.5 | 9.7 ± 3 | 0.667 |
18th week post-treatment | 13.8 ± 2.2 | 12 ± 3.2 | |
p* | < 0.001 | < 0.001 | |
Activity level | |||
Post-treatment | 13.4 ± 1.7 | 12.2 ± 3.7 | |
6th week post-treatment | 16.7 ± 3.1 | 14.8 ± 3.1 | 0.775 |
18th week post-treatment | 19.2 ± 1.7 | 17.5 ± 2.6 | |
p* | < 0.001 | < 0.001 | |
ROM | |||
Post-treatment | 27.5 ± 3.6 | 24 ± 4.3 | |
6th week post-treatment | 30.8 ± 4.5 | 27.2 ± 4.3 | 0.09 |
18th week post-treatment | 34.9 ± 5.1 | 29.1 ± 4.5 | |
p* | < 0.001 | < 0.001 | |
Strength | |||
Post-treatment | 6.4 ± 3 | 4.7 ± 4 | |
6th week post-treatment | 9.8 ± 3.2 | 9 ± 5 | 0.425 |
18th week post-treatment | 12.2 ± 4.2 | 11.4 ± 5.5 | |
p* | < 0.001 | < 0.001 |